Phesi and Krystelis collaborate to launch new Diversity, Equity, and Inclusion Data Service for clinical development
Phesi announces its partnership with Krystelis, a world leading provider of medical writing and clinical trial transparency services, to launch its new Diversity, Equity, and Inclusion (DEI) Data Service. The new service harnesses data from Phesi Trial Accelerator™ and Krystelis’ writing services to empower sponsors to improve diversity from the trial planning stage onwards
Depression now one of the top five most studied disease areas in clinical development, finds new Phesi global analysis
Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity.
New Phesi global analysis sees breast cancer retain position as most studied disease area in 2022
The analysis of 80,917 trial records reveals that breast cancer retained its position as the most-studied disease area, followed by COVID-19. Three of the top five most-studied disease areas fell within oncology, with prostate cancer the third most-studied disease, solid tumours fourth, and stroke fifth. Both prostate cancer and stroke enter the top five in 2022, replacing non-small cell lung cancer and multiple myeloma in 2021.
Number of collagen clinical trials more than doubled since 2010, Phesi analysis shows
Phesi, a global provider of patient-centric data analytics, has today published a new analysis of 2,358 clinical trials involving collagen to highlight the growing investment being placed into the protein. The analysis shows a steady, linear increase in new collagen clinical trials over the previous decade (Fig. 1). In the first 10 months of 2022, there were more than 225 new trials into collagen, compared with 125 in 2012.